Regeneron Pharmaceuticals reported $2.71B in Debt for its fiscal quarter ending in June of 2026.





Debt Change Date
AbbVie USD 70.82B 2.04B Jun/2026
Agenus USD 35.54M 2.34M Mar/2025
Agios Pharmaceuticals USD 35.74M 4.46M Mar/2026
Alnylam Pharmaceuticals USD 2.48B 1.21B Sep/2026
Amgen USD 57.32B 2.72B Mar/2026
Astellas Pharma JPY 565.95B 265.47B Mar/2026
AstraZeneca USD 32.24B 1.68B Jun/2026
Biogen USD 7.69B 398.3M Sep/2026
BioMarin Pharmaceutical USD 4.2B 2.76B Jun/2026
Bristol-Myers Squibb USD 42.88B 2.18B Sep/2026
Eli Lilly USD 54.91B 11.54B Jun/2026
Gilead Sciences USD 26.25B 4.07B Jun/2026
GlaxoSmithKline GBP 18.24B 818M Jun/2026
Incyte USD 38.27M 1.16M Jun/2026
Ionis Pharmaceuticals USD 1.91B 425.5M Jun/2026
J&J USD 49.04B 5.95B Jun/2026
Kyowa Hakko Kirin JPY 28.75B 5.04B Dec/2024
Merck USD 53.91B 4.79B Jun/2026
Moderna USD 1.3B 7M Mar/2026
Neurocrine Biosciences USD 401.8M 4.4M Jun/2026
Novartis USD 49.01B 2.02B Jun/2026
Novartis USD 47B 14.98B Mar/2026
Pfizer USD 63.19B 536M Jun/2026
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Regeneron Pharmaceuticals USD 2.71B 400K Jun/2026
Roche Holding CHF 33.03B 1.41B Jun/2025
Sanofi EUR 20.02B 1.73B Mar/2026
Sarepta Therapeutics USD 1.04B 3.08M Mar/2026
Teva Pharmaceutical Industries USD 16.91B 187M Mar/2026
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
United Therapeutics USD 200M 100M Mar/2025
Vertex Pharmaceuticals USD 1.98B 8.9M Jun/2026